Cannabinoid Treatment Reversed MDMA-Induced Memory Deficits but Not Decision-Making Impairment in Rats
Chronic co-administration of a cannabinoid with MDMA reversed ecstasy-induced working memory deficits in rats treated during either puberty or adulthood, but did not fix MDMA-impaired effort-based decision making.
Quick Facts
What This Study Found
Rats received MDMA, the cannabinoid agonist WIN55,212-2, both, or vehicle for 25 days during either puberty (PD40-65) or adulthood (PD80-105). Ten days after treatment, MDMA alone impaired working memory in the novel object recognition test. Co-administration of the cannabinoid with MDMA reversed this memory deficit in both age groups.
However, in an effort-based T-maze task (choosing between easy low-reward and difficult high-reward options), adult MDMA-treated rats showed impaired decision making that the cannabinoid did not reverse. These selective effects suggest the cannabinoid-MDMA interaction differentially affects hippocampal (memory) and corticolimbic (decision-making) circuits.
Key Numbers
MDMA 7.5 mg/kg + WIN 1.2 mg/kg for 25 days. WIN reversed MDMA memory deficits in both pubertal and adult rats. WIN did not reverse MDMA decision-making deficits in adults. Acute MDMA decreased high-reward choices (cost-aversive behavior).
How They Did This
Rat study with 4 treatment groups (vehicle, MDMA 7.5 mg/kg, WIN 1.2 mg/kg, MDMA+WIN) across 2 age windows (pubertal PD40-65, adult PD80-105). Behavioral testing 10 days after treatment ended: novel object recognition and effort-based T-maze. Acute drug challenge during T-maze testing.
Why This Research Matters
MDMA and cannabis are frequently combined by young adults. This study shows the interaction is complex: the cannabinoid protected against some MDMA-induced cognitive damage (memory) but not others (decision-making). This has implications for understanding the long-term effects of polysubstance use.
The Bigger Picture
The selective protection of hippocampal but not corticolimbic function suggests that cannabinoid-MDMA interactions are circuit-specific. This complexity means the real-world effects of combining these substances are not simply additive or protective, but depend on which brain systems are assessed.
What This Study Doesn't Tell Us
Rat model with specific doses that may not reflect human co-use patterns. Only one cannabinoid agonist and dose tested. The 10-day washout period is relatively short. Behavioral tasks measure specific cognitive domains and may not capture the full picture. Only male rats were studied.
Questions This Raises
- ?Does cannabis co-use protect against MDMA memory damage in humans?
- ?What mechanism allows cannabinoid protection of hippocampal but not corticolimbic function?
- ?Would CBD (non-psychoactive) provide the same protection as a full agonist?
Trust & Context
- Key Stat:
- Cannabinoid reversed MDMA memory damage but not decision-making impairment
- Evidence Grade:
- Animal study with selective behavioral effects; preliminary evidence for circuit-specific cannabinoid-MDMA interactions.
- Study Age:
- Published in 2013. Polysubstance interaction research continues to reveal complex, domain-specific effects.
- Original Title:
- Chronic co-administration of the cannabinoid receptor agonist WIN55,212-2 during puberty or adulthood reverses 3,4 methylenedioxymetamphetamine (MDMA)-induced deficits in recognition memory but not in effort-based decision making.
- Published In:
- Pharmacology, biochemistry, and behavior, 106, 91-100 (2013)
- Authors:
- Schulz, Sybille(2), Becker, Thorsten, Nagel, Ulrich, von Ameln-Mayerhofer, Andreas, Koch, Michael
- Database ID:
- RTHC-00732
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Does cannabis protect against ecstasy brain damage?
In this rat study, a cannabinoid reversed MDMA-induced memory deficits, suggesting some protection for hippocampal function. However, it did not protect against decision-making impairment, meaning the "protection" was partial and circuit-specific. This complexity means cannabis does not simply prevent or cause MDMA brain damage in a blanket fashion.
Does it matter when the drug exposure happens?
The cannabinoid reversed MDMA memory deficits regardless of whether exposure occurred during puberty or adulthood. However, the decision-making impairment was seen only in adult-treated rats, suggesting age-specific vulnerability in corticolimbic circuits. This age-dependent pattern adds another layer of complexity to understanding polysubstance effects.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00732APA
Schulz, Sybille; Becker, Thorsten; Nagel, Ulrich; von Ameln-Mayerhofer, Andreas; Koch, Michael. (2013). Chronic co-administration of the cannabinoid receptor agonist WIN55,212-2 during puberty or adulthood reverses 3,4 methylenedioxymetamphetamine (MDMA)-induced deficits in recognition memory but not in effort-based decision making.. Pharmacology, biochemistry, and behavior, 106, 91-100. https://doi.org/10.1016/j.pbb.2013.03.011
MLA
Schulz, Sybille, et al. "Chronic co-administration of the cannabinoid receptor agonist WIN55,212-2 during puberty or adulthood reverses 3,4 methylenedioxymetamphetamine (MDMA)-induced deficits in recognition memory but not in effort-based decision making.." Pharmacology, 2013. https://doi.org/10.1016/j.pbb.2013.03.011
RethinkTHC
RethinkTHC Research Database. "Chronic co-administration of the cannabinoid receptor agonis..." RTHC-00732. Retrieved from https://rethinkthc.com/research/schulz-2013-chronic-coadministration-of-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.